Previous Close | 3.4350 |
Open | 3.7000 |
Bid | 3.3800 x 100 |
Ask | 3.5100 x 100 |
Day's Range | 3.3000 - 3.7000 |
52 Week Range | 2.4200 - 5.8100 |
Volume | |
Avg. Volume | 62,145 |
Market Cap | 88.11M |
Beta (5Y Monthly) | 1.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings Date | May 09, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.00 |
Q1 2024 Eton Pharmaceuticals Inc Earnings Call
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
We feel now is a pretty good time to analyse Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) business as it appears the...